MARKET

CMRX

CMRX

Chimerix
NASDAQ
0.8888
+0.0044
+0.50%
Opening 10:43 04/22 EDT
OPEN
0.8860
PREV CLOSE
0.8844
HIGH
0.8982
LOW
0.8800
VOLUME
108.58K
TURNOVER
0
52 WEEK HIGH
1.570
52 WEEK LOW
0.8800
MARKET CAP
79.29M
P/E (TTM)
-0.9593
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at CMRX last week (0415-0419)?
Weekly Report · 5h ago
Weekly Report: what happened at CMRX last week (0408-0412)?
Weekly Report · 04/15 10:34
WHO's Tedros Adhanom Ghebreyesus Posts On X "In #DRC alone, more than 4500 cases of #mpox and almost 300 deaths have been reported this year. That is triple the number reported at this time last year. The recent surge in cases and deaths among children is of particular concern, along with the re-emergence of Clade One in central Africa...."
Benzinga · 04/11 14:09
Weekly Report: what happened at CMRX last week (0401-0405)?
Weekly Report · 04/08 10:37
Weekly Report: what happened at CMRX last week (0325-0329)?
Weekly Report · 04/01 10:36
Weekly Report: what happened at CMRX last week (0318-0322)?
Weekly Report · 03/25 10:39
Chimerix Board Changes: Machado Resigns, Kozin Appointed
Patrick Machado has announced his resignation from the Board of Directors of Chimerix. Marc Kozin has been appointed as a Class III director of the company. Machado cited no disagreements with the company’s operations or policies. CMRX stock is down 10% in the past week.
TipRanks · 03/21 12:42
Press Release: Chimerix Appoints Marc D. Kozin to Board of Directors
Chimerix Appoints Marc D. Kozin to Board of Directors Veteran Industry Executive Brings More Than 35 years of Corporate Strategy Experience. Patrick Machado has announced his retirement from the Chimerix Board effective at the 2024 Annual Meeting of Stockholders in June.
Dow Jones · 03/21 11:00
More
About CMRX
Chimerix, Inc. is a biotechnology company. The Company is focused on developing medicines that address unmet medical needs. The Company's product Imipridones is a cancer therapy that provides ONC201, which is in clinical-stage development for H3 K27M-mutant glioma as its lead indication. In addition, imipridone ONC206 is in dose-escalating clinical trials. Imipridones target specific G protein-coupled receptors (GPCRs) and mitochondrial caseinolytic protease P (ClpP), resulting in cancer cell death. The Company's product Imipridone chemical scaffold provides an opportunity to target GPCRs and ClpP with tunable specificity and modality, which enables therapeutic use for cancer and other diseases. Its ONC206 is an imipridone, Dopamine Receptor D2 (DRD2) antagonist and ClpP agonist. Its ONC212 is an imipridone, an investigational agonist of the orphan GPCR tumor suppressor GPR132, as well as ClpP. Its CMX521 is a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2.

Webull offers Chimerix Inc stock information, including NASDAQ: CMRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CMRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CMRX stock methods without spending real money on the virtual paper trading platform.